Donor stem cell transplant after donor cell targeting in youth
Part of Blood & lymphatic clinical trials.
This trial studies a special donor stem cell transplant where the donor’s immune cells are reduced, aiming to lower harmful immune attacks after transplant. It may help children and young adults with certain high-risk blood cancers or rare bone marrow disorders.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 1 month and under 60 years old
- Your doctors believe a stem cell transplant (HSCT) is appropriate, and you have serious blood disease that could benefit
- Your health is stable enough (expected to live more than 10 weeks, and heart/kidney/liver function are within limits)
- A compatible donor is required, with at least a 5 out of 10 match, and specific match at HLA gene sites (A, B, C, DQB1, DRB1)
- You do not have certain exclusions like pregnancy or a prior transplant, and you don’t have uncontrolled infections
- You (or a parent/guardian) can give consent, and if you could become pregnant, you agree to effective birth control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a type of stem cell transplant that removes certain immune cells (alpha-beta T cells and CD19 B cells) from the donor cells. This may help prevent graft-versus-host disease and other complications in patients with blood cancers who do not have a matched sibling donor.
This trial studies a type of stem cell transplant (bone marrow transplant) that uses a donor who is only half-matched to the patient, often a parent or sibling. It is for children and young adults with certain blood diseases, including sickle cell disease, thalassemia, bone marrow failure, and immune disorders. The transplant aims to replace the diseased blood-forming cells with healthy ones from the donor.
This trial provides a special type of stem cell transplant for people under 22 years old who don't have a fully matched sibling donor. It uses a method to remove certain cells from the donor's stem cells to reduce the risk of graft-versus-host disease, where the donor cells attack the patient's body.
This study tests a special stem cell transplant for children and young adults with certain high-risk blood cancers or bone marrow diseases. It uses a half-matched family donor and a technique to remove specific cells, which may lower the risk of side effects and help the body accept the new cells.
This trial uses a special type of stem cell transplant that removes certain cells to reduce complications. It may help people with blood diseases, immune problems, or other conditions that can be treated with a stem cell transplant.
This expanded-access study offers a specific type of stem cell transplant preparation that removes certain immune cells (CD3 and CD19) from donor stem cells. It is for children who need a transplant but do not have a fully matched sibling donor and whose team cannot use the hospital’s usual matching device protocol.
Hear when a new Hematologic Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.